PharmaCorp Rx Inc.
PCRX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.17M | 1.02M | 213.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.17M | 1.02M | 213.00K | -- | -- |
| Cost of Revenue | 2.60M | 646.10K | 140.90K | -- | -- |
| Gross Profit | 1.57M | 376.70K | 72.10K | -- | -- |
| SG&A Expenses | 2.53M | 1.91M | 940.20K | 513.40K | 427.50K |
| Depreciation & Amortization | 208.80K | 72.00K | 16.40K | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.34M | 2.63M | 1.10M | 513.40K | 427.50K |
| Operating Income | -1.17M | -1.61M | -884.50K | -513.40K | -427.50K |
| Income Before Tax | -860.50K | -1.46M | -818.60K | -435.70K | -347.80K |
| Income Tax Expenses | -76.10K | 400.00 | -200.00 | -- | -- |
| Earnings from Continuing Operations | -0.78 | -1.46 | -0.82 | -0.44 | -0.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 25.90K | 100.00 | -1.20K | -- | -- |
| Net Income | -758.70K | -1.46M | -819.70K | -435.70K | -347.80K |
| EBIT | -1.17M | -1.61M | -884.50K | -513.40K | -427.50K |
| EBITDA | -838.00K | -1.21M | -433.90K | -- | -- |
| EPS Basic | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.02 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.02 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 306.62M | 209.36M | 116.48M | 81.11M | 81.04M |
| Average Diluted Shares Outstanding | 306.62M | 209.36M | 116.48M | 81.11M | 81.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |